---
title: Novartis AG (NVS)
layout: default
nav_order: 53
---

# Novartis AG
{: .fs-9 }

{: .label .label-purple }

Moat: 2/5

{: .label .label-blue }

Management: 3/5

{: .label .label-green }

Catalyst: 2/5

{: .label .label-yellow }

Pessimistic value: $175 B

Novartis, a global healthcare company, possesses elements of a narrow moat based on intangible assets (brand name and patents) and a large distribution network. However, the pharmaceutical industry's dynamic nature, patent expirations, and increasing competition create significant challenges to the long-term durability of these competitive advantages.
{: .fs-6 .fw-300 }

[Investor Relations](https://www.google.com/search?q=NVS+investor+relations){: .btn .btn-primary .fs-5 .mb-4 .mb-md-0 .mr-2 }
[Previous Earnings Calls](https://discountingcashflows.com/company/NVS/transcripts/){: .btn .fs-5 .mb-4 .mb-md-0 }

---

{: .warning } 
>The moat rating, management rating, catalyst score, and valuation are meant to reflect a pessimistic outlook, signaling potential competitive pressures and limited growth. This ensures that some margin of safety is already baked in.


**Moat:**

Novartis earns a rating of **2 out of 5** for its moat. 

* **Intangible Assets:** Novartis has several established, high-profile products with brand-name recognition, including Cosentyx and Entresto. Their oncology portfolio and upcoming treatments like Kisqali provide some pricing power. Patents afford some protection, but this is constantly under threat from generic competition and biosimilars. The constant need for R&D investment and acquisitions to maintain its drug pipeline indicates the vulnerability of its existing patents.  (Source: 2015-2020 Novartis Annual Reports)
* **Distribution Network:** As a major pharmaceutical company, Novartis benefits from its size and global reach, enabling it to distribute its products efficiently and negotiate favorable terms with payers and suppliers. This creates a cost advantage and customer captivity, strengthening its moat. However, this is not as strong a moat as a network effect. (Source: "Moat's Importance" in Counterpoint Global Insights)
* **Emerging Market Risk:**  Novartis has increased revenues from emerging markets such as China and India. However, country risk should be factored into valuations of companies in these markets, potentially leading to a discount. (Source: "Valuation in Emerging Markets" in *The Little Book of Valuation*)


**Management:**

Novartis' management earns a rating of **3 out of 5**. 

* **Capital Allocation:** The acquisition of Alcon was a significant financial misstep and was ultimately sold off for less than what Novartis had hoped to receive. There have been other strategic missteps, with Novartis failing to capitalize on some profitable opportunities due to excessive focus on generic drug manufacturing. (Source: 2019 Novartis Annual Report and Earnings Call, Q4 2017-Q3 2018)
* **Compensation:** While executive compensation is high, it is generally in line with industry peers and increasingly tied to performance, suggesting some shareholder alignment. However, the significant stock option grants and share buybacks also benefit executives directly, potentially incentivizing short-term focus. (Source: 2023 Novartis Annual Report and Proxy Statement)
* **Communication:** Novartis has improved communication with investors, providing detailed financial reporting in SEC filings and holding regular earnings calls. However, some of the company's discussions about "core" earnings can sometimes create confusion when trying to discern its core financial performance. (Source: Novartis Earnings Calls 2022-2023)
* **Insider Ownership:** Insider ownership is relatively low, with most executives owning less than 1% of the outstanding shares. This level of insider ownership does not signal significant management alignment with the interests of outside shareholders. (Source: Novartis 2023 Proxy Statement)
* **Board Independence:**  With the appointment of a new Chairman, there have been a few steps to increase board independence with more than 75% of the board being independent.  This aligns well with Graham's ideals in the Intelligent Investor about corporate governance. (Source: *The Essays of Warren Buffett*)
* **Long-Term Performance Plan:** The compensation of the Executive Committee (EC) is determined, in part, based on the three-year Long-Term Performance Plan (LTPP). Between 2020 and 2022, the LTPP tracked total shareholder return (TSR) versus global health care peers. This provides management with an incentive to maintain above-average TSR, though it has a limited impact on individual business unit performance. (Source: Novartis Annual Reports)


**Catalyst:**

Novartis' catalyst rating is **2 out of 5**. 

* **Pipeline:**  Novartis' pipeline has several promising drugs in development, particularly in the oncology, immunology, and neuroscience areas.  These have the potential to boost revenues and earnings in the future, though significant risk remains due to long development timelines, potential regulatory hurdles, and competition. The success of Kisqali and Entresto provide hope that the company can continue to create promising new drug products and commercialize them successfully.  (Source: Novartis 2023 Annual Report)
* **Sandoz Spinoff:** The recent completion of the Sandoz spinoff allows management to focus its resources and efforts on the core pharmaceutical business and should unlock value over time. (Source: Novartis 2023 Annual Report)
* **Cost-Cutting and Productivity:** Management initiatives to streamline operations and improve productivity may yield results in the medium to long term. However, the company's record in implementing such initiatives has been mixed in the past, as cost-cutting estimations are often easier said than done. (Source: *The Little Book of Valuation*)
* **Restructuring:** Novartis is undergoing a period of restructuring, which could lead to increased profitability if successfully implemented. There is, however, an associated risk that the transition will negatively affect short-term performance and that management will not successfully follow through on all its promises. (Source: *The Little Book of Valuation*)

**Valuation:**

Using a discounted cash flow (DCF) model and being a bit pessimistic about assumptions (growth rate, profit margin, costs of equity & capital, etc.), I estimate Novartis' fair value to be approximately **$175 billion**. 

* **Methodology:** DCF using free cash flow to the firm (FCFF)
* **Key Assumptions:**
    * Revenue growth: 3% for the next 5 years, declining to a stable growth rate of 1% (below global GDP growth) in perpetuity. (Justification: Accounting for increased competition and patent expirations)
    * Operating margin: Gradual improvement to 20% over the next five years, remaining stable thereafter. (Justification: Novartis has consistently been trying to improve margins, but increasing competition and pricing pressures may impede significant margin expansion.)
    * Reinvestment Rate: Estimated to be 40% of after-tax operating income in stable growth to support assumed growth rate. 
    * Cost of equity: 8% (Justification: Novartis has a beta around 0.80, and is an established company, so this cost of equity reflects a slight discount because Novartis is not exposed to as much risk as some of its competitors)
    * Cost of debt: 3% (Justification: Based on Novartis' credit rating, this represents a slightly higher cost of debt than its existing debt structure)
    * Tax rate: 20% (Justification: Reflecting blended tax rate for Switzerland and other countries Novartis operates in.) 

> **Detailed Calculations:**
> * Calculate the free cash flow (FCFF) for the next five years using the assumed revenue growth and margin.
> * Calculate the terminal value using the stable growth perpetuity formula: Terminal Value = (FCFF<sub>5</sub> * (1 + g)) / (WACC - g)
> * Discount the FCFFs and terminal value back to the present using the WACC. 
> * Adjust for net debt, minority interests, and other claims to get the value of equity.
> * Divide the value of equity by the number of outstanding shares to arrive at a value per share.


> *Caveat:* This is an approximate valuation for illustrative purposes. Actual results may vary as business conditions, risk, and growth vary from the assumed inputs.




**Specific Concerns:**

> 2023Q1 Conference Call: Novartis mentioned regulatory challenges in bringing certain products to the market. Further investigations by regulators and government agencies will probably continue and increase scrutiny. 
These regulatory challenges could hurt revenue growth.

> 2022Q1 Conference Call: Concerns around pricing pressures. Novartis mentioned pricing controls and pressure on prices by governments and insurers, primarily in developed markets, potentially affecting profitability, which are relevant to our assessment.

**Potential Catalysts:**

* **New Drug Approvals:** Novartis has several drugs in development in promising therapeutic areas such as oncology, immunology, neuroscience, and cardiovascular disease. Successful clinical trials and FDA approvals can lead to significant increases in share price.
* **Strategic Acquisitions or Partnerships:** Novartis has been active in pursuing strategic alliances and acquisitions. Successful acquisitions or partnerships, especially in high-growth areas, could create significant upside.
* **Cost-Cutting and Efficiency Improvements:** Novartis has been implementing several initiatives to cut costs and streamline operations. These initiatives may improve profitability and create value for shareholders over time.


**Closing Thoughts:**

Novartis presents a complicated valuation due to the dynamic nature of the pharmaceutical industry and increasing competition from generic drugs and biosimilars. While the company has attractive assets and a promising pipeline, investors should approach the stock with a margin of safety and be conservative in making their valuation assumptions.  Given the uncertainty surrounding its future performance and high current valuation, the upside potential seems limited.


***

**Additional Notes:**

*  The valuation excludes cash holdings and accounts receivable shown on the balance sheet. In valuation modeling, there are arguments for netting cash against debt and adding accounts receivable to core operating profit before interest, taxes, depreciation and amortization (EBITDA). However, given potential difficulties in valuing cash and accounts receivables, the most realistic treatment would be to ignore them. (Source: *The Little Book of Valuation*)
* The valuation is conducted from the perspective of a long-term investor. For a shorter-term investor, additional factors not explicitly modeled, such as quarterly earnings surprises, may affect a stock price in any direction.Â 
* The valuation method presented is based on the intrinsic value of a company or asset. It does not guarantee an automatic increase in market price or value. Prices and valuations are in constant flux, affected by various elements, particularly in emerging markets.  



**Disclaimer:**

This is not investment advice. This analysis is based on publicly available information and personal interpretations. Please conduct your own research before making any investment decisions.